☆ 4.7 Review

Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis

JOURNAL OF CLINICAL MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Biochemistry & Molecular Biology

Sphingosine 1-Phosphate as Essential Signaling Molecule in Inflammatory Skin Diseases

Burkhard Kleuser et al.

Summary: Sphingolipids are crucial molecules in the mammalian epidermis, playing important roles in the structure of the epidermal layer and regulation of immune cells. The sphingolipid sphingosine 1-phosphate (S1P) is involved in skin cell proliferation and differentiation, and dysregulation of its signaling pathways is associated with inflammatory skin diseases.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials

S Vermeire et al.

Journal of Crohns & Colitis (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study

S Danese et al.

Journal of Crohns & Colitis (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Probiotic Yeast from Miso Ameliorates Stress-Induced Visceral Hypersensitivity by Modulating the Gut Microbiota in a Rat Model of Irritable Bowel Syndrome

Nao Sugihara et al.

Summary: Recent research suggests that Zygosaccharomyces sapae (strain I-6), a probiotic yeast isolated from miso, a traditional Japanese fermented food, may improve symptoms of irritable bowel syndrome. The study found that administering strain I-6 suppressed the increase in stool pellets and visceral hypersensitivity induced by stress, and reversed the loss of tight junction protein occludin. 6-Glucan from strain I-6 also had a similar effect. Treatment with strain I-6 altered the diversity of gut microbiota and induced changes in bacterial occupancy.

GUT AND LIVER (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation

Joana Torres et al.

JOURNAL OF CROHNS & COLITIS (2023)

添加到收藏夹

Article Medicine, General & Internal

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

William J. Sandborn et al.

Summary: Etrasimod, a selective S1P receptor modulator, demonstrated efficacy and safety as an induction and maintenance therapy for patients with moderately to severely active ulcerative colitis. The trials showed a higher proportion of patients achieving clinical remission with Etrasimod compared to placebo at both induction and maintenance periods. This novel treatment option has the potential to address unmet needs in ulcerative colitis patients.

LANCET (2023)

添加到收藏夹

Article Nutrition & Dietetics

Dietary Sources of Anthocyanins and Their Association with Metabolome Biomarkers and Cardiometabolic Risk Factors in an Observational Study

Hamza Mostafa et al.

Summary: This observational study explored the association between anthocyanin intake and cardiometabolic risk. Results revealed specific associations between anthocyanins and certain plasma metabolites, some of which were inversely correlated with visceral adipose tissue. These findings suggest a potential link between anthocyanin intake and cardiometabolic health benefits.

NUTRIENTS (2023)

添加到收藏夹

Review Nutrition & Dietetics

Effects of Diet and Exercise on Circadian Rhythm: Role of Gut Microbiota in Immune and Metabolic Systems

Yidan Cai et al.

Summary: There is a close relationship between the intestinal microbiota and the circadian rhythm, regulated by the central-biological-clock system and the peripheral-biological-clock system. The intestinal flora also exhibits rhythmic oscillation. Poor diet and sedentary lifestyle can lead to immune and metabolic diseases. Numerous studies have shown that through diet, including fasting, and exercise, the human body can be influenced in its immune regulation, energy metabolism, and expression of biological-clock genes via the intestinal microbiota as the vector, resulting in reduced disease incidence rates. This article mainly discusses the effects of diet and exercise on the intestinal flora, immune, and metabolic systems from the perspective of the circadian rhythm, providing a more effective approach to prevent immune and metabolic diseases by modulating the intestinal microbiota.

NUTRIENTS (2023)

添加到收藏夹

Review Nutrition & Dietetics

An Assessment of Mushroom Consumption on Cardiometabolic Disease Risk Factors and Morbidities in Humans: A Systematic Review

Cassi N. Uffelman et al.

Summary: Mushroom consumption may have positive effects on cardiometabolic health, particularly on triglycerides and hs-CRP levels. However, the current evidence is limited and inconsistent, with most studies being of poor quality. Further high-quality experimental and observational research is needed to confirm these potential benefits.

NUTRIENTS (2023)

添加到收藏夹

Review Nutrition & Dietetics

Dietary Implications of the Bidirectional Relationship between the Gut Microflora and Inflammatory Diseases with Special Emphasis on Irritable Bowel Disease: Current and Future Perspective

Tariq Aziz et al.

Summary: The immune system plays a vital role in protecting the human body against infections and inflammatory diseases. Diet and meal patterns, specifically the Mediterranean diet and Western diet, have a significant impact on immune function. The intake of Mediterranean-style foods promotes the growth of healthy gut bacteria, while Western-style foods contribute to the growth of harmful gut bacteria, leading to inflammation and weakened immune system.

NUTRIENTS (2023)

添加到收藏夹

Correction Medicine, General & Internal

The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein) (vol 401, pg 568, 2023)

D. K. Heyland et al.

LANCET (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OZANIMOD IN ULCERATIVE COLITIS

Daniel Tatosian et al.

GASTROENTEROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment

Tim Raine et al.

JOURNAL OF CROHNS & COLITIS (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease

Bram Verstockt et al.

Summary: Immune cell trafficking is a crucial process in the intestinal immune response, particularly in inflammatory bowel disease. Inhibition of lymphocyte egress from the lymph nodes to the bloodstream has shown promise in reducing inflammation in immune-mediated disorders. This review summarizes the key mediators and mechanisms involved in immune cell trafficking and explores the potential of S1P receptor modulators as therapeutic agents in the treatment of inflammatory bowel disease.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Silvio Danese et al.

LANCET (2022)

添加到收藏夹

Review Microbiology

Human gut microbiota in health and disease: Unveiling the relationship

Muhammad Afzaal et al.

Summary: The human gut contains a complex microbial community, which forms a connecting axis with other organs and plays a vital role in host-microbe interactions. Dysbiosis of the gut microbiota is linked to various human diseases. Understanding the role of gut microbiota in health and disease is crucial for maintaining health and treating diseases.

FRONTIERS IN MICROBIOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

S694 Comparative Efficacy and Safety of Ozanimod vs Adalimumab and Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis

Marla C. Dubinsky et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study

Severine Vermeire et al.

Summary: The study showed that treatment with 2 mg Etrasimod has significant benefits and good safety for patients with ulcerative colitis. Most patients maintained their clinical response, clinical remission, or endoscopic improvement status at the end of treatment.

JOURNAL OF CROHNS & COLITIS (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Gut microbiota and their metabolites in cardiovascular disease

Valerie LBI. Jansen et al.

Summary: The gut microbiome can affect the development and progression of diseases such as obesity, diabetes, atherosclerosis, and arterial thrombosis. Gut microbiome-derived metabolites have been shown to predict arterial thrombosis, potentially influencing platelet function and Von Willebrand factor production. In certain autoimmune disorders, gut commensals may play a role in disease pathogenesis.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Medicine, General & Internal

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Brian G. Feagan et al.

Summary: The study assessed the efficacy and safety of filgotinib in treating ulcerative colitis, with the results showing that 200 mg of filgotinib was more effective than placebo in inducing and maintaining clinical remission.

LANCET (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study

William J. Sandborn et al.

Summary: The study examined the long-term safety and efficacy of Ozanimod in patients with moderately to severely active ulcerative colitis, showing continued benefits in clinical response, endoscopic improvement, and biomarker measures with 1 mg daily dosage. The high rate of study participation and long-term benefit indicates the potential of Ozanimod as a treatment option for UC patients.

JOURNAL OF CROHNS & COLITIS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis

William J. Sandborn et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis

Joseph D. Feuerstein et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Is there a role for therapeutic sphingolipids in inflammatory bowel disease?

Tommaso Lorenzo Parigi et al.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Ozanimod: First Approval

Yvette N. Lamb

DRUGS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Tu1852 PHARMACOKINETICS AND PHARMACODYNAMICS OF OPL-002, A HIGHLY SELECTIVE S1P1R MODULATOR, IN HEALTHY ADULT VOLUNTEERS.

Allison Luo et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

Brian G. Feagan et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹

Article Oncology

Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer

Luciana Petti et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Rheumatology

Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study

Yoshiya Tanaka et al.

LUPUS (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts

Tamara Perez-Jeldres et al.

INFLAMMATORY BOWEL DISEASES (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

Tamara Perez-Jeldres et al.

FRONTIERS IN PHARMACOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Interfering with leukocyte trafficking in Crohn's disease

Sujata Biswas et al.

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis

Jing Jin et al.

FRONTIERS IN PHARMACOLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Jeffrey A. Cohen et al.

LANCET NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

Giancarlo Comi et al.

LANCET NEUROLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence

Pablo Olivera et al.

DIGESTIVE AND LIVER DISEASE (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease

Amy Hemperly et al.

INFLAMMATORY BOWEL DISEASES (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life

Paschalis Paschos et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study

Jonathan Q. Tran et al.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-I-Phosphate Receptor Modulator

Jonathan Q. Tran et al.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Next generation of small molecules in inflammatory bowel disease

Pablo Olivera et al.

GUT (2017)

添加到收藏夹

Article Immunology

Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease

T. Karuppuchamy et al.

MUCOSAL IMMUNOLOGY (2017)

添加到收藏夹

Review Immunology

JAK inhibition in inflammatory bowel disease

Pablo Olivera et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)

添加到收藏夹

Review Immunology

Novel therapeutic targets for inflammatory bowel disease

Marjorie Argollo et al.

JOURNAL OF AUTOIMMUNITY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator

Jonathan Q. Tran et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

添加到收藏夹

Review Medicine, General & Internal

Ulcerative colitis

Ryan Ungaro et al.

LANCET (2017)

添加到收藏夹

Review Immunology

Modulation of sphingosine-1-phosphate in inflammatory bowel disease

Laurent Peyrin-Biroulet et al.

AUTOIMMUNITY REVIEWS (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity

F. L. Scott et al.

BRITISH JOURNAL OF PHARMACOLOGY (2016)

添加到收藏夹

Review Biochemistry & Molecular Biology

Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators

Pierre-Eric Juif et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

Giulia Roda et al.

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)

添加到收藏夹

Article Pharmacology & Pharmacy

Bitopic Sphingosine 1-Phosphate Receptor 3 (S1P3) Antagonist Rescue from Complete Heart Block: Pharmacological and Genetic Evidence for Direct S1P3 Regulation of Mouse Cardiac Conduction

M. Germana Sanna et al.

MOLECULAR PHARMACOLOGY (2016)

添加到收藏夹

Review Medicine, Research & Experimental

Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy

Richard L. Proia et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

添加到收藏夹

Review Gastroenterology & Hepatology

Biologic agents for IBD: practical insights

Silvio Danese et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial

Andrea Vaclavkova et al.

LANCET (2014)

添加到收藏夹

Review Immunology

Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs

Jason G. Cyster et al.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

William J. Sandborn et al.

GASTROENTEROLOGY (2012)

添加到收藏夹

Article Clinical Neurology

Sphingosine 1-phosphate (S1P) Physiology and the effects of S1P receptor modulation

Timothy Hla et al.

NEUROLOGY (2011)

添加到收藏夹

Review Immunology

The outs and the ins of sphingosine-1-phosphate in immunity

Sarah Spiegel et al.

NATURE REVIEWS IMMUNOLOGY (2011)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review: the costs of ulcerative colitis in Western countries

R. D. Cohen et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

David Marsolais et al.

NATURE REVIEWS DRUG DISCOVERY (2009)

添加到收藏夹

Article Pharmacology & Pharmacy

"Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets

K. Takabe et al.

PHARMACOLOGICAL REVIEWS (2008)

添加到收藏夹

Review Immunology

The alliance of sphingosine-1-phosphate and its receptors in immunity

Juan Rivera et al.

NATURE REVIEWS IMMUNOLOGY (2008)

添加到收藏夹

Article Medicine, General & Internal

Infliximab for induction and maintenance therapy for ulcerative colitis

P Rutgeerts et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

添加到收藏夹

Review Gastroenterology & Hepatology

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

EV Loftus

GASTROENTEROLOGY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.